Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key

GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma

Showing 15 of 15 matching drugs for RXRB — including drugs targeting any of its 28 synthetic-lethal partners , sorted by total cancer coverage.

Drug	Target	Relationship	Reposition	#cancers
nivolumab or pembrolizumab (dependent upon approved indication), metformin, rosiglitazone	RXRB	Direct		3
alitretinoin	RXRB	Direct	yes	0
bexarotene	RXRB	Direct	yes	0
adagrasib	KRAS	SSL via KRAS	yes	2
sotorasib	KRAS	SSL via KRAS	yes	2
biopsy, biospecimen collection, ceralasertib, computed tomography, echocardiography, multigated acquisition scan, positron emission tomography, trastuzumab deruxtecan	ATR	SSL via ATR		1
ce-mark approved laa closure devices, acetylsalicylic acid, clopidogrel, dabigatran, rivaroxaban, apixaban, edoxaban, phenprocoumon, warfarin	TP53	SSL via TP53		1
ceralasertib, olaparib, durvalumab	ATR	SSL via ATR		1
cisplatin, carboplatin, etoposide, durvalumab, ceralasertib	ATR	SSL via ATR		1
enzastaurin, bevacizumab, enzyme-inducing antiepileptic drugs (eiaed), non-enzyme inducing antiepileptic drugs (neiaed)	PIK3R1	SSL via PIK3R1		1
enzastaurin, lomustine	PIK3R1	SSL via PIK3R1		1
enzastaurin, temozolomide, radiation therapy	PIK3R1	SSL via PIK3R1		1
clofarabine	POLD1	SSL via POLD1	yes	0
gemcitabine	POLD1	SSL via POLD1	yes	0
gemcitabine hydrochloride	POLD1	SSL via POLD1	yes	0

Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.